{
  "drug_info": {
    "source_claim_id": [1, 69, 83],
    "name": "TALVEY®",
    "class": "first in class TCR BsAb targeting GPRC5D",
    "target": "GPRC5D",
    "approval_date": {
      "EU": "August 2023"
    },
    "data_source_summary": "Consolidated data based on the Claims Matrix, reflecting longer-term follow-up from the MonumenTAL-1 trial (e.g., ASCO 2025, EHA 2024/2025 presentations).",
    "references": [
      "TALVEY® SmPC (EU), 2025.",
      "Chari A et al. Lancet Haematol 2025; 12(4):e269–e281.",
      "Einsele H et al. Adv Ther 2024; 41(4):1576–e1593."
    ]
  },
  "indication": {
    "source_claim_id": [8],
    "primary": "Monotherapy for the treatment of adult patients with TCE R/R MM who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody, and have demonstrated disease progression on the last therapy.",
    "requirements": [
      "Received at least 3 prior therapies",
      "Including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody"
    ],
    "references": [
      "TALVEY® SmPC (EU), 2025."
    ]
  },
  "mechanism": {
    "source_claim_id": [38, 41, 47, 76, 81],
    "target_description": "GPRC5D is a novel target highly expressed on MM cells, independent of BCMA expression.",
    "action": "TALVEY® is a BsAb that targets GPRC5D expressing malignant plasma cells and CD3 on T cells.",
    "advantages": [
      "Preserves patients’ B cells to help maintain their immune response.",
      "GPRC5D has little to no expression on normal human haematopoietic cells, including B cells and bone marrow progenitors."
    ],
    "references": [
      "TALVEY® SmPC (EU), 2025.",
      "Kodama T et al. Mol Cancer Ther 2019; 18(9):1555–1564.",
      "Atamaniuk J et al. Eur J Clin Invest 2012; 42(9):953–960.",
      "Einsele H et al. Adv Ther 2024; 41(4):1576–1593.",
      "Schinke C et al. Blood Adv 2025; doi:10.1182/bloodadvances.2025016613.",
      "Smith EL et al. Sci Transl Med 2019; 11(485):eaau7746."
    ]
  },
  "clinical_trials": {
    "primary_trial": {
      "source_claim_id": [7, 84, 86, 88],
      "name": "MonumenTAL-1",
      "id": "NCT04634552",
      "design": "Phase I/II, single arm, open label, multicentre study.",
      "total_patients": 375,
      "patient_population": "adult patients with triple class exposed R/R MM",
      "references": [
        "TALVEY® SmPC (EU), 2025.",
        "Rasche L et al. Presented at: American Society of Clinical Oncology (ASCO) Congress; 30 May–3 June 2025; Chicago, IL (Poster no. 96).",
        "Chari A et al. N Engl J Med 2022; 387(24):2232–2244."
      ],
      "endpoints": {
        "source_claim_id": [89],
        "primary": "overall response rate (ORR)",
        "secondary": [
          "depth of response",
          "duration of response (DOR)",
          "time to response (TTR)",
          "minimal residual disease (MRD) negativity rate",
          "progression free survival (PFS)",
          "overall survival (OS)",
          "safety"
        ],
        "references": [
          "Chari A et al. Lancet Haematol 2025; 12(4):e269–e281.",
          "Rasche L et al. Presented at: American Society of Clinical Oncology (ASCO) Congress; 30 May–3 June 2025; Chicago, IL (Poster no. 96)."
        ]
      },
      "cohorts_long_term_fu": {
        "references": [
            "Rasche L et al. Presented at: American Society of Clinical Oncology (ASCO) Congress; 30 May–3 June 2025; Chicago, IL (Poster no. 96)."
        ],
        "cohorts": [
          {
            "source_claim_id": [86, 90, 134],
            "description": "Prior T-cell-redirecting therapy naïve",
            "dosing_schedule": "0.4 mg/kg weekly SC",
            "patient_count": 143,
            "median_follow_up_months": 38.2
          },
          {
            "source_claim_id": [86, 90, 134],
            "description": "Prior T-cell-redirecting therapy naïve",
            "dosing_schedule": "0.8 mg/kg biweekly SC",
            "patient_count": 154,
            "median_follow_up_months": 31.2
          },
          {
            "source_claim_id": [86, 90, 134],
            "description": "Prior T-cell-redirecting therapy exposed",
            "dosing_schedule": "0.4 mg/kg weekly SC or 0.8 mg/kg biweekly SC",
            "patient_count": 78,
            "median_follow_up_months": 30.3
          }
        ]
      }
    }
  },
  "efficacy_results": {
    "references": [
        "Rasche L et al. Presented at: American Society of Clinical Oncology (ASCO) Congress; 30 May–3 June 2025; Chicago, IL (Poster no. 96).",
        "Chari A et al. Lancet Haematol 2025; 12(4):e269–e281."
    ],
    "weekly_dosing": {
      "source_claim_id": [4, 20, 27, 28, 29, 123, 124, 136, 138, 142],
      "overall_response_rate_percent": 74.1,
      "complete_response_rate_or_better_percent": 32.9,
      "vgpr_or_better_percent": 59.5,
      "median_duration_of_response_months": 9.5,
      "median_pfs_months": 7.5,
      "median_os_months": 34,
      "os_rate_36_month_percent": 49.3,
      "mrd_negativity_rate_percent": 64.3,
      "median_ttr_months": 1.2
    },
    "biweekly_dosing": {
      "source_claim_id": [4, 20, 27, 28, 29, 125, 126, 136, 138, 143],
      "overall_response_rate_percent": 69.5,
      "complete_response_rate_or_better_percent": 40.3,
      "vgpr_or_better_percent": 59.1,
      "median_duration_of_response_months": 17.5,
      "median_pfs_months": 11.2,
      "median_os_months": "Not Reached",
      "os_rate_36_month_percent": 60.8,
      "mrd_negativity_rate_percent": 65.2,
      "median_ttr_months": 1.3
    },
    "prior_tcell_therapy_exposed": {
      "source_claim_id": [4, 20, 28, 29, 127, 128, 132, 136, 138, 141],
      "overall_response_rate_percent": 66.7,
      "complete_response_rate_or_better_percent": 42.3,
      "vgpr_or_better_percent": 55.1,
      "median_duration_of_response_months": 19.2,
      "median_pfs_months": 7.7,
      "median_os_months": 28.3,
      "os_rate_36_month_percent": 44.6,
      "mrd_negativity_rate_percent": 57.1,
      "median_ttr_months": 1.2
    },
    "subgroup_analysis": {
      "prior_bcma_exposure_details": {
        "source_claim_id": [26, 31, 33, 42],
        "references": ["Rasche L et al. Presented at: European Hematology Association (EHA) Congress; 13–16 June 2024; Madrid, Spain (Poster no. P915)."],
        "subgroups": [
          {
            "subgroup": "Prior CAR-T therapy",
            "orr_percent": 71.4,
            "median_pfs_months": 12.3
          },
          {
            "subgroup": "Prior BsAb therapy",
            "orr_percent": 57.7,
            "median_pfs_months": 4.1
          }
        ]
      },
      "by_prior_lines_of_therapy_biweekly": {
        "source_claim_id": [14, 15, 16],
        "references": ["Ye JC et al. Presented at: International Myeloma Society (IMS) Annual Meeting; 25–28 September 2024; Rio de Janeiro, Brazil (Poster no. P-098)."],
        "subgroups": [
          {
            "lines_of_therapy": "<=4",
            "median_dor_months": "Not Reached",
            "median_pfs_months": 17.8,
            "os_rate_24_month_percent": 75
          },
          {
            "lines_of_therapy": ">=5",
            "median_dor_months": 13,
            "median_pfs_months": 8.5,
            "os_rate_24_month_percent": 59
          }
        ]
      }
    }
  },
  "comparison_to_standard_of_care": {
    "source_comparison_studies": [
      "LocoMMotion",
      "MoMMent"
    ],
    "standard_of_care_outcomes": {
      "source_claim_id": [62, 63, 64],
      "summary": "Clinical outcomes observed with real-world Standard of Care treatments in TCE R/R MM patients from pooled analysis.",
      "overall_response_rate_percent": 32.5,
      "median_duration_of_response_months": 8.3,
      "median_pfs_months": 4.6,
      "median_os_months": 14.8,
      "references": [
        "Weisel K et al. Presented at: European Hematology Association (EHA) Congress; 12–15 June 2025; Milan, Italy (Poster no. PS1783)."
      ]
    },
    "talvey_indirect_comparison_vs_soc": {
      "source_claim_id": [30, 70, 71, 72, 73, 74, 75],
      "references": [
        "Einsele H et al. Adv Ther 2024; 41(4):1576–1593.",
        "Einsele H et al. Presented at: European Hematology Association (EHA) Congress; 12–15 June 2025; Milan, Italy (Poster no. PS1737).",
        "Weisel K et al. Presented at: European Hematology Association (EHA) Congress; 12–15 June 2025; Milan, Italy (Poster no. PS1783)."
      ],
      "weekly_dosing_vs_soc": {
        "response_likelihoods_fold_increase": {
          "orr": 2.6,
          "vgpr": 4.6,
          "cr": 30.8
        },
        "median_pfs_months": {
          "talvey": 7.5,
          "soc": 4.1
        },
        "median_os_months": {
          "talvey": "Not Reached",
          "soc": 9.2
        }
      },
      "biweekly_dosing_vs_soc": {
        "response_likelihoods_fold_increase": {
          "orr": 2.6,
          "vgpr": 5,
          "cr": 52.2
        },
        "median_pfs_months": {
          "talvey": 14.2,
          "soc": 4.1
        },
        "median_os_months": {
          "talvey": "Not Reached",
          "soc": 10.3
        }
      }
    }
  },
  "sequential_therapy_outcomes": {
    "source_claim_id": [115, 116, 117, 118, 119, 121, 122],
    "summary": "Efficacy of subsequent T-cell redirecting therapies was retained after patients had received TALVEY®.",
    "references": [
      "Sanchez L et al. Presented at: 65th American Society of Hematology (ASH) Annual Meeting and Exposition; 9–12 December 2023; San Diego, CA (Presentation no. 2007)."
    ],
    "post_talvey_CAR_T": {
      "orr_percent": 64.7,
      "patient_count": "11/17",
      "cr_or_better_percent": 35
    },
    "post_talvey_anti_BCMA_CAR_T": {
      "orr_percent": 77.8,
      "patient_count": "7/9"
    },
    "post_talvey_non_GPRC5D_BsAb": {
      "orr_percent": 60.9,
      "patient_count": "14/23",
      "cr_or_better_percent": 30
    },
    "post_talvey_anti_BCMA_BsAb": {
      "orr_percent": 57.9,
      "patient_count": "11/19"
    }
  },
  "safety_profile": {
    "adverse_events_summary": {
      "source_claim_id": [46],
      "references": ["TALVEY® SmPC (EU), 2025."],
      "events_over_40_percent": [
        { "event": "CRS", "frequency_percent": 77 },
        { "event": "Taste changes", "frequency_percent": 72 },
        { "event": "Hypogammaglobulinaemia", "frequency_percent": 67 },
        { "event": "Nail disorder", "frequency_percent": 56 },
        { "event": "Musculoskeletal pain", "frequency_percent": 48 },
        { "event": "Anaemia", "frequency_percent": 47 },
        { "event": "Fatigue", "frequency_percent": 43 },
        { "event": "Weight decreased", "frequency_percent": 40 }
      ]
    },
    "discontinuation_rate_due_to_aes_percent": {
      "source_claim_id": [50, 51, 52],
      "references": ["Chari A et al. Lancet Haematol 2025; 12(4):e269–e281."],
      "weekly_dosing": 5,
      "biweekly_dosing": 9,
      "prior_tcell_therapy": 5
    },
    "key_aes_details": {
      "crs": {
        "source_claim_id": [167, 168, 169],
        "references": ["TALVEY® SmPC (EU), 2025.", "Rasche L et al. Presented at: American Society of Clinical Oncology (ASCO) Congress; 30 May–3 June 2025; Chicago, IL (Poster no. 96)."],
        "weekly_dosing_incidence_percent": 79,
        "biweekly_dosing_incidence_percent": 75.3,
        "notes": "The majority of CRS events were Grade 1 or 2, and generally occurred during the step up dosing phase or with the initial treatment dose."
      },
      "icans": {
        "source_claim_id": [170],
        "references": ["Chari A et al. Lancet Haematol 2025; 12(4):e269–e281.","TALVEY® SmPC (EU), 2025."],
        "weekly_dosing_incidence_percent": 11,
        "biweekly_dosing_incidence_percent": 10,
        "prior_tcell_therapy_incidence_percent": 4
      },
      "infections": {
        "source_claim_id": [161, 162],
        "references": ["Rasche L et al. Presented at: American Society of Clinical Oncology (ASCO) Congress; 30 May–3 June 2025; Chicago, IL (Poster no. 96)."],
        "weekly_dosing_incidence_percent": 60.8,
        "weekly_dosing_grade_3_4_percent": 23.1,
        "biweekly_dosing_incidence_percent": 70.8,
        "biweekly_dosing_grade_3_4_percent": 21.4
      }
    },
    "newly_identified_signals": [
      {
        "source_claim_id": [145],
        "references": ["Rasche L et al. Presented at: American Society of Clinical Oncology (ASCO) Congress; 30 May–3 June 2025; Chicago, IL (Poster no. 96)."],
        "signal": "Ataxia/balance disorders",
        "prevalence": "Low (1 patient in the biweekly cohort)",
        "source_observation": "Identified during the >=2.5 year follow up of the MonumenTAL 1 trial"
      }
    ]
  },
  "patient_reported_outcomes": {
    "source_claim_id": [172, 173, 174, 175, 176],
    "references": ["Schinke C et al. Cancer 2025; 131(14):e35927."],
    "source_population": "Phase II of the MonumenTAL 1 trial in 118 patients receiving TALVEY® 0.8 mg/kg biweekly.",
    "summary": "Patients with R/R MM who received biweekly TALVEY® reported meaningful improvements in HRQoL measures, including pain and fatigue.",
    "improvements_by_cycle_21": {
      "eortc_qlq_c30_domains_ls_mean_change": {
        "global_health_status": "+5",
        "physical_functioning": "+5",
        "emotional_functioning": "+12.5",
        "fatigue": "+4",
        "pain_scores": "-11"
      }
    }
  },
  "dosing_administration": {
    "source_claim_id": [92, 93, 100, 101, 102, 105],
    "references": ["TALVEY® SmPC (EU), 2025."],
    "routes": "Subcutaneous (SC)",
    "schedules": ["Weekly (0.4 mg/kg)", "Biweekly (0.8 mg/kg)"],
    "step_up_dosing": "Required to reduce the risk of CRS.",
    "premedication": "Pretreatment with a corticosteroid, antihistamine and antipyretic is required 1–3 hours prior to administration of each step up dose.",
    "monitoring": "Patients should be monitored for 48 hours after administration of all doses within the step up dosing phase for signs and symptoms of CRS and ICANS.",
    "treatment_duration": "Until disease progression or unacceptable toxicity."
  },
  "real_world_evidence": {
    "outpatient_administration": {
      "source_claim_id": [106, 107, 108, 109],
      "references": [
        "Soefje S et al. Presented at: European Hematology Association (EHA) Congress; 12–15 June 2025; Milan, Italy (Poster no. PS1764).",
        "Lund T et al. Eur J Haematol 2025; 115(4):358–366."
      ],
      "feasibility": "Outpatient administration is considered feasible and is expected to provide benefits to patients and healthcare centres.",
      "findings": "AEs associated with step up dosing were manageable in outpatient settings, and patients had a reduced length of hospital stay vs. inpatient delivery."
    },
    "efficacy_and_safety_outcomes": {
      "source_claim_id": [178, 179],
      "references": [
        "Janakiram M et al. Presented at: 66th American Society of Hematology (ASH) Annual Meeting and Exposition; 7–10 December 2024; San Diego, CA (Abstract no. 3368).",
        "Rasche L et al. Presented at: American Society of Clinical Oncology (ASCO) Congress; 30 May–3 June 2025; Chicago, IL (Poster no. 96)."
      ],
      "source": "Retrospective real world study from 7 IMF MM academic centers (N=118).",
      "orr_percent": 65,
      "conclusion": "The ORR is consistent with the ORR of 67% achieved in BCMA TCR therapy exposed patients in the MonumenTAL 1 trial."
    }
  },
  "treatment_guideline_recommendations": [
    {
      "source_claim_id": [61],
      "references": ["Dimopoulos MA et al. Nat Rev Clin Oncol 2025; 22(9):680–700."],
      "guideline": "2025 EHA EMN Guidelines",
      "recommendation": "TALVEY® is recommended for use at second or subsequent relapse."
    }
  ]
}